Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista de Ciencias Médicas de Pinar del Río
versión On-line ISSN 1561-3194
Resumen
DOPICO-RAVELO, Daniesky et al. Nimotuzumab in patients with COVID-19 in Pinar del Río. Rev Ciencias Médicas [online]. 2022, vol.26, n.4 Epub 01-Jul-2022. ISSN 1561-3194.
Introduction:
COVID-19 is an emerging viral disease of the XXI century, being a respiratory disease that can present in severe forms due to the state of systemic hyperinflammation generated by it, for which several treatments have been used in Cuba to improve respiratory ventilation, avoid hyperinflammation and prevent sequelae such as pulmonary fibrosis, where one of these drugs has been the monoclonal antibody Nimotuzumab; for playing an important role against the epidermal growth factor receptor.
Objective:
to characterize the use of Nimotuzumab in patients with COVID-19 in the Clinical Surgical Teaching Hospital "León Cuervo Rubio" of Pinar del Río, from July to October 2021.
Methods:
an observational, descriptive and transversal study was carried out in patients with COVID-19 treated at the "León Cuervo Rubio" Clinical Surgical Teaching Hospital. A total of 419 patients were studied, selected by simple random sampling, where their clinical histories were reviewed.
Results:
53,59 % were male, between 60 and 79 years old (45,82 %). The risk factors with the highest incidence were arterial hypertension (71,36 %) and diabetes mellitus (21,96 %). One patient was reported with adverse reactions with chills and fever and 79,47 % recovered, with 20,53 % dying.
Conclusions:
the predominant sex was male, between 60 and 79 years old, with risk factors of arterial hypertension and diabetes mellitus; where both clinical and radiological recovery was excellent and with high drug safety.
Palabras clave : PNEUMONIA; COVID-19; PROTOCOLS.